Bcr-Abl tyrosine-kinase inhibitors (TKI) are the first-line therapy for most patients with chronic myelogenous leukemia (CML). More than 90% of CML cases are caused by a chromosomal abnormality that results in the formation of a so-called Philadelphia chromosome. This abnormality is a consequence of fusion between the Abelson (Abl) tyrosine kinase gene at chromosome 9 and the break point cluster (Bcr) gene at chromosome 22, resulting in a chimeric oncogene (Bcr-Abl) and a constitutively active Bcr-Abl tyrosine kinase that has been implicated in the pathogenesis of CML. Compounds have been developed to selectively inhibit the tyrosine kinase.
适用于细胞培养的Holo-Human transferrin (Holo-TRF)是一种转铁蛋白受体配体,可通过受体依赖的内吞作用介导转铁蛋白偶联脂质体进入白血病细胞,而过量的游离Holo-Human transferrin则可通过饱和转铁蛋白受体 (Transferrin Receptor) 阻断这一过程;此外,适用于细胞培养的Holo-Human transferrin还能将抗BCR-ABL siRNA或asODN靶向递送至白血病细胞,促进BCR-ABL mRNA的序列特异性下调、Bcr-Abl蛋白水平降低并诱导白血病细胞产生细胞毒性,并可通过向巨噬细胞吞噬体泡内的鸟分枝杆菌复合菌群提供铁离子而成为吡啶甲酸抗MAC活性的拮抗剂,因此可用于慢性粒细胞白血病和鸟分枝杆菌复合体感染的相关研究。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号